TAF is a more potent reformulation of Viread, which is itself widely used for HBV but does not often result in seroconversion. The other two drugs offer hope, but HBV is a tough nut to crack because it integrates into the host genome.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”